Tourette Syndrome (TS) is a developmental neuropsychiatric disorder which affects between 3 in 1000 individuals and 1 in 100 individuals (1-3). It is characterized by the presence of both motor and vocal tics and follows a waxing and waning course, often with improvement or remission in adulthood (4-7). While cellular and molecular mechanisms underlying TS pathophysiology remain uncertain, multiple lines of evidence point to the involvement of dopaminergic (DA) neurotransmission and abnormalities in the corticostriatal- thalamic-cortical (CTSC) circuits (8, 9). More recent post mortem data highlights abnormalities in striatal gamma-Aminobutyric acid (GABA)ergic interneurons (10, 11).
